A. A normal healthy individual
B. A patient with mild systemic disease
C. A patient with severe systemic disease that it not in capacitating
D. None of the above
A. Inverse agonist
B. Antagonist
C. Agonist
D. Partial agonist
A. Side effect
B. Toxicity effect
C. Idiosyncratic effect
D. Drug on Drug effect
A. Morphine
B. Nitroglycerine
C. Propranolol
D. Salicylates
A. Volume of distribution
B. Clearance
C. Rate of administration
D. Half life
A. Tetracycline
B. Cimetidine
C. Rifampicin
D. Phenobarbitone
A. Penicillamine
B. E.D.T.A
C. Desferrixamine
D. B.A.L
A. Anti-hypertensives
B. Anti-diabetics
C. Anticoagulants
D. Anti-fibrinolytics
A. Range of disease in which the drug beneficial
B. Maximal intensity of response that can be produced by the drug
C. The therapeutic does range of the drug
D. The therapeutic index of the drug
A. It is the proportion (fraction) of unchanged drug that reaches the systemic circulation
B. Biovailability of an orally administered drug can be calculated by comparing the area under cure (o-a) after oral and intravenous (IV) administration
C. Low oral biovailability always and necessarily mean poor absorption
D. Biovailability can be determined from plasma concentration or urinary excretion data